Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Drug Treatment Reduces Chronic Pain Following Shingles

Published: Friday, February 07, 2014
Last Updated: Friday, February 07, 2014
Bookmark and Share
New drug EMA401 reduce pain and did not cause any serious side effects.

A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

The researchers hope that the drug might also be effective against other causes of chronic neuropathic pain, such as diabetes, HIV, nerve injury and cancer chemotherapy, as it targets a mechanism that is not targeted by any existing therapies and has fewer side effects.

Drugs available now have limited success at treating neuropathic pain and often have unpleasant or disabling side effects.

It is estimated that around 190,000 people in the UK get shingles every year, most of them aged over 50. It is caused when a dormant viral infection of a nerve is reactivated, resulting in a painful rash. In most cases, the shingles rash lasts a few weeks, but in some cases the permanent nerve damage caused by the virus results in a chronic neuropathic pain called post-herpetic neuralgia. Around one in 10 people with shingles experiences post-herpetic neuralgia and, once established, it usually causes life-long suffering.

In a study involving 183 patients with post-herpetic neuralgia in six countries, the new drug EMA401 was found to reduce pain and did not cause any serious side effects.

Lead author Professor Andrew Rice, from the Department of Surgery and Cancer at Imperial College London, said: "Conventional painkillers don't tend to help people with severe chronic neuropathic pain and most available treatments have modest efficacy and/or are limited by side effects. We are therefore keen to find new ways of providing these people with some relief.

"A positive trial like this in such a challenging condition as post-herpetic neuralgia, for a drug that acts in a new way, is unusual and very exciting. We hope that the new drug will ultimately offer hope for patients who aren't helped by current treatments."

The study, a phase 2 trial, compared EMA401 with a placebo, with participants taking two pills a day for four weeks. Fifty-eight per cent of participants taking the drug found it effective, reducing pain by at least 30 per cent.

Spinifex Pharmaceuticals, which owns the drug, now plans to conduct a larger trial, possibly testing higher doses of the drug for longer periods of time.

"We are looking forward to seeing how EMA401 performs in a larger trial in people with post-herpetic neuralgia, where we will explore higher doses, and in trials where we will analyze its efficacy in other chronic pain conditions. Identifying the characteristics of the patients who do get good pain relief from EMA401 will also be an important avenue for research," added Professor Rice.

Tom McCarthy, CEO of Spinifex Pharmaceuticals, said: "There is a clear need for new treatments that bring patients pain relief with fewer side effects. In addition to post-herpetic neuralgia, we see broad potential for EMA401 to treat a range of chronic painful conditions such as pain due to osteoarthritis and diabetes. We look forward to delivering on the further development of EMA401."

Spinifex's clinical program for EMA401 includes a clinical trial in the treatment of neuropathic pain in patients after cancer chemotherapy, which is being conducted by Professor Praveen Anand at Imperial College London. Professor Anand's group also conducted key clinical tissue research which led up to the trials.

Professor Rice works with patients with neuropathic pain at Chelsea and Westminster Hospital, where he is a Consultant in Pain Medicine. He has worked with Spinifex through Imperial Consultants on the pre-clinical development of the new drug since 2005.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gene Therapy for Cystic Fibrosis Shows Encouraging Trial Results
A therapy that replaces the faulty gene responsible for cystic fibrosis in patients' lungs has produced encouraging results in a major UK trial.
Friday, July 03, 2015
Alcoholic Hepatitis Treatments Fail to Keep Patients Alive
The study is published in the New England Journal of Medicine.
Friday, May 01, 2015
Study Finds Potential New Target to Treat Asthma Attacks Brought on by Colds
Results suggest that IL-25 could be a target for possible treatments to prevent asthma attacks.
Tuesday, October 07, 2014
First Gene Therapy Trial Launched for Heart Patients with Mechanical Pumps
Patient received new gene therapy at Harefield Hospital, London.
Tuesday, August 12, 2014
Stem Cells Show Promise for Stroke in Pilot Study
Findings are published in the journal Stem Cells Translational Medicine.
Saturday, August 09, 2014
Statins Slow the Progression of Advanced MS in Clinical Trial
The work is published in the Lancet.
Saturday, March 29, 2014
Statins Slow the Progression of Advanced MS in Clinical Trial
The work is published in the Lancet.
Friday, March 21, 2014
Malaria Drug Target Raises Hopes for New Treatments
Scientists identify way to stop malaria parasites from multiplying.
Thursday, December 26, 2013
Badgers Ultimately Responsible for Around Half of TB in Cattle, Study Estimates
The findings are published in the journal PLOS Currents: Outbreaks.
Tuesday, November 05, 2013
Multi-drug Pills Help People Stick to Heart Disease Prevention Regimens
Findings are published in the Journal of the American Medical Association.
Friday, September 27, 2013
£73m Powerhouse of Biomedical Research Opens at Imperial College London
Designed to expand and accelerate the translation of scientific discoveries.
Wednesday, November 21, 2012
Cystic Fibrosis Gene Therapy Programme Gets Green Light with Public Funding
Gene therapy trial for CF to begin in March.
Friday, March 16, 2012
One-a-day Heart Polypill to be Tested in new International Trial
Researchers to explore whether a new, low cost, one-a-day combined 'polypill' could reduce the risk of heart attacks and related problems.
Monday, May 17, 2010
University Research Contributes £45 Billion a Year to the UK Economy, According to new Impact Study
A new economic impact assessment of university research suggests that the £3.5 billion a year currently spent on publicly funded research generates an additional annual output of £45 billion in UK companies.
Monday, March 15, 2010
HIV Vaccine Failure Probably Caused By Virus Used, Says New Research
Researchers say, failure was probably caused by the immune system reacting to the virus 'shell' used to transmit the therapy around the body.
Tuesday, November 17, 2009
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!